Showing results (21-30 of 121) with videos related to
Sort By:
Pageof 13
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|November 7, 2018
[The health economics of cancer screening in Germany: Which population-based interventions are cost-effective?]Michael Schlander, Chih-Yuan Cheng, Tao RanExpert Review of Pharmacoeconomics & Outcomes Research|October 15, 2014
Budget impact analysis of drugs for ultra-orphan non-oncological diseases in EuropeMichael Schlander, Charles Christian Adarkwah, Afschin GandjourMedicine, Health Care, and Philosophy|August 16, 2021
Resource allocation in the Covid-19 health crisis: are Covid-19 preventive measures consistent with the Rule of Rescue?Julian W März, Søren Holm, Michael SchlanderValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare DiseasesMichael Schlander, Charalabos-Markos Dintsios, Afschin GandjourSocial Science & Medicine (1982)|November 4, 2004
Empiricism, ethics and orthodox economic theory: what is the appropriate basis for decision-making in the health sector?Jeff Richardson, John McKieAustralia and New Zealand Health Policy|November 19, 2008
Increasing the options for reducing adverse events: Results from a modified Delphi techniqueJeff Richardson, John McKieHealth Economics, Policy, and Law|August 9, 2011
Social preferences for the inclusion of indirect benefits in the evaluation of publicly funded health services: results from an Australian surveyJohn McKie, Jeff RichardsonHealth Economics, Policy, and Law|May 9, 2018
Social preferences for prioritising the treatment of disabled and chronically ill patients: beyond the order effectJohn Mckie, Jeff RichardsonHealth Policy (Amsterdam, Netherlands)|June 18, 2017
Social preferences for prioritizing the treatment of severely ill patients: The relevance of severity, expected benefit, past health and lifetime healthJohn McKie, Jeff RichardsonPageof 13